



RaQualia
innovators for life

**Motilin Receptor Agonist
for Gastrointestinal Motility Disorders
Worldwide Partnering Opportunity**

1. Executive Summary

- Mechanism of Action
 - Motilin receptor agonist
- Target Indications
 - Upper gastrointestinal (GI) motility disorders
 - » Functional dyspepsia (FD), gastroparesis, gastroesophageal reflux disease (GERD)
- Target Product Profile
 - Novel prokinetics for patients sub-optimally controlled with present therapies
 - » First-line therapy for reducing abdominal discomfort in FD postprandial distress syndrome (PDS) and gastroparesis
 - » Effective for GERD patients who are refractory to proton pump inhibitors (PPI) treatment
- Non-Clinical Profile
 - Highly potent motilin receptor agonist with an EC_{50} value of 0.20 nM
 - Oral activity demonstrated in animal models
 - No particular issues in pharmacokinetics, metabolism, and safety
- IP Status
 - COM* expiry beyond 20 years including up to 5 years extension

*: Composition of Matter

2. Table of Contents

	Title	Slide No.
1.	Executive Summary	2
2.	Table of Contents	3
3.	Product Concept	4
4.	Scientific Rationale	5
5.	Unmet Medical Needs	6
6.	Market Opportunities	7
7.	Compound Attributes	8
	7.1. Compound Information	9
	7.2. Non-Clinical Pharmacology	10
	7.3. Non-Clinical Pharmacokinetics	17
	7.4. Toxicology	18
	7.5. Summary of RQ-00201894	19
8.	Competitors	20

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011